Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

395 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Distribution differences in prognostic copy number alteration profiles in IDH-wild-type glioblastoma cause survival discrepancies across cohorts.
Umehara T, Arita H, Yoshioka E, Shofuda T, Kanematsu D, Kinoshita M, Kodama Y, Mano M, Kagawa N, Fujimoto Y, Okita Y, Nonaka M, Nakajo K, Uda T, Tsuyuguchi N, Fukai J, Fujita K, Sakamoto D, Mori K, Kishima H, Kanemura Y. Umehara T, et al. Acta Neuropathol Commun. 2019 Jun 18;7(1):99. doi: 10.1186/s40478-019-0749-8. Acta Neuropathol Commun. 2019. PMID: 31215469 Free PMC article.
Revisiting the definition of glioma recurrence based on a phylogenetic investigation of primary and re-emerging tumor samples: a case report.
Umehara T, Arita H, Miya F, Achiha T, Shofuda T, Yoshioka E, Kanematsu D, Nakagawa T, Kinoshita M, Kagawa N, Fujimoto Y, Hashimoto N, Kiyokawa H, Morii E, Tsunoda T, Kanemura Y, Kishima H. Umehara T, et al. Brain Tumor Pathol. 2022 Oct;39(4):218-224. doi: 10.1007/s10014-022-00438-1. Epub 2022 Jun 6. Brain Tumor Pathol. 2022. PMID: 35666326
11C-methionine-18F-FDG dual-PET-tracer-based target delineation of malignant glioma: evaluation of its geometrical and clinical features for planning radiation therapy.
Hirata T, Kinoshita M, Tamari K, Seo Y, Suzuki O, Wakai N, Achiha T, Umehara T, Arita H, Kagawa N, Kanemura Y, Shimosegawa E, Hashimoto N, Hatazawa J, Kishima H, Teshima T, Ogawa K. Hirata T, et al. Among authors: umehara t. J Neurosurg. 2019 Sep 21;131(3):676-686. doi: 10.3171/2018.4.JNS1859. J Neurosurg. 2019. PMID: 30239314
Molecular characteristics and clinical outcomes of elderly patients with IDH-wildtype glioblastomas: comparative study of older and younger cases in Kansai Network cohort.
Fukai J, Arita H, Umehara T, Yoshioka E, Shofuda T, Kanematsu D, Kodama Y, Mano M, Kinoshita M, Okita Y, Nonaka M, Uda T, Tsuyuguchi N, Sakamoto D, Uematsu Y, Nakao N, Mori K, Kanemura Y. Fukai J, et al. Among authors: umehara t. Brain Tumor Pathol. 2020 Apr;37(2):50-59. doi: 10.1007/s10014-020-00363-1. Epub 2020 May 2. Brain Tumor Pathol. 2020. PMID: 32361941
TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
Fujimoto K, Arita H, Satomi K, Yamasaki K, Matsushita Y, Nakamura T, Miyakita Y, Umehara T, Kobayashi K, Tamura K, Tanaka S, Higuchi F, Okita Y, Kanemura Y, Fukai J, Sakamoto D, Uda T, Machida R, Kuchiba A, Maehara T, Nagane M, Nishikawa R, Suzuki H, Shibuya M, Komori T, Narita Y, Ichimura K. Fujimoto K, et al. Among authors: umehara t. Acta Neuropathol. 2021 Aug;142(2):323-338. doi: 10.1007/s00401-021-02337-9. Epub 2021 Jun 20. Acta Neuropathol. 2021. PMID: 34148105
395 results